Use of red blood cell fatty-acid profiles as biomarkers in cardiac disease

Biomarkers in Medicine

Volumn 3, Issue 1, 2009, Pages 25-32

  von Schacky, Clemens ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Omegametrix GmbH   (Germany)

Author keywords

Congestive heart failure; Coronary artery disease; Docosahexaenoic acid; Eicosapentaenoic acid; Omega 3 Index; Sudden cardiac death

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DOCOSAHEXAENOIC ACID; FATTY ACID; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PLACEBO;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DISEASE MARKER; DRUG MECHANISM; ERYTHROCYTE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; INCIDENCE; LIPID COMPOSITION; NONHUMAN; PREDICTION; REVIEW; RISK FACTOR; SUDDEN DEATH;

EID: 68049131230     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/17520363.3.1.25     Document Type: Review

References (60)

1. Zipes DP, Camm AJ, Borggrefe M et al.: ACC/AHA/ESC guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society for Cardiology Committee for Practice guidelines (writing committee to develop guidelines for management of patients with ventricular Arrhythmias and the prevention of sudden cardiac death). Eur. Heart J. 27, 2099-2140 (2006).
2. Anand SS, Islam S, Rosengren A et al.: INTERHEART investigators: risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur. Heart J. 29, 932-940 (2008).
3. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts); Graham I, Atar D, Borch-Johnsen K et al.: European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur. Heart J. 28, 2375-2414 (2007).
4. Smulders YM, Thijs A, Twisk JW: New cardiovascular risk determinants do exist and are clinically useful. Eur. Heart J. 29, 436-440 (2008).
5. Wang TJ: New cardiovascular risk factors exist, but are they clinically useful? Eur. Heart J. 29, 441-444 (2008).
6. Dickstein K, Cohen-Solal A, Filippatos G et al.: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure (2008): the task force for the diagnosis and treatment of acute and chronic heart failure (2008) of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J. 29, 2388-2442 (2008).
7. Braunwald E: Biomarkers in heart failure. N. Engl J. Med. 358, 2148-2159 (2008).
8. Harris WS, von Schacky C: The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev. Med. 39, 212-220 (2004).
9. Harris WS, Poston WC, Haddock CK: Tissue n-3 and n-6 fatty acids and risk for coronary heart disease events. Atherosclerosis 193, 1-10 (2007).
10. Harris WS, von Schacky C, Park Y: Establishing uniform analytical methods for RBC Omega-3 fatty acids: an intercontinental pilot study. ISSFAL 78 (2008) (Abstract).
11. Harris WS: The Omega-3 Index as a risk factor for coronary heart disease. Am. J. Clin. Nutr. 87, S1997-S2002 (2008).
12. von Schacky C, Fischer S, Weber PC: Long-term effects of dietary marine ?-3 fatty acids upon plasma and cellular lipids, platelet function and eicosanoid formation in humans. J. Clin. Invest. 76, 1626-1631 (1985).
13. von Schacky C, Fahrer C, Fischer S: Catabolism of leukotriene B5 in humans. J. Lipid Res. 31, 1831-1838 (1990).
14. Kaminski WE, Jendraschak E, Kiefl R, von Schacky C: Dietary Omega-3 fatty acids lower levels of PDGF mRNA in human mononuclear cells. Blood 81, 1871-1879 (1993).
15. von Schacky C, Weber PC: Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J. Clin. Invest. 76, 2446-2450 (1985).
16. Harris WS, Sands SA, Windsor SL, Ali HA et al.: Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. Circulation 110, 1645-1649 (2004).
17. Metcalf RG, James MJ, Gibson RA et al.: Effects of fish-oil supplementation on myocardial fatty acids in humans. Am. J. Clin. Nutr. 85, 1222-1228 (2007).
18. Sands SA, Reid KJ, Windsor SL, Harris WS: The impact of age, body mass index, and fish intake on the EPA and DHA content of human erythrocytes. Lipids 40, 343-347 (2005).
19. Itomura M, Fujioka S, Hamazaki K et al.: Factors influencing EPA+DHA levels in red blood cells in Japan. In vivo 22, 131-135 (2008).
20. Plourde M, Cunnane SC: Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. Appl. Physiol. Nutr. Metab. 32, 619-634 (2007).
21. Friedman AN, Moe SM, Perkins SM, Li Y, Watkins BA: Fish consumption and Omega-3 fatty acid status and determinants in long-term hemodialysis. Am. J. Kidney Dis. 47, 1064-1071 (2006).
22. Iso H, Kobayashi M, Ishihara J et al.: JPHC Study Group. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center- Based (JPHC) Study Cohort I. Circulation 113, 195-202 (2006).
23. Siscovick DS, Raghunathan TE, King I et al.: Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. J. Am. Med. Assoc. 275, 836-837 (1995).
24. Albert CM, Campos H, Stampfer MJ: Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N. Engl J. Med. 346, 1113-1118 (2002).
25. Marchioli R, Barzi F, Bomba E et al.: On behalf of the GISSI Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction. Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarcto Miocardio (GISSI)-Prevenzione. Circulation 105, 1897-1903 (2002).
26. Yokoyama M, Origasa H, Matsuzaki M et al.: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369, 1090-1098 (2007).
27. Block RC, Harris WS, Reid KJ, Sands SA, Spertus JA: EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. Atherosclerosis 197, 821-828 (2008).
28. Sun Q, Ma J, Campos H et al.: Blood concentrations of individual long-chain n-3 fatty acids and risk of nonfatal myocardial infarction. Am. J. Clin. Nutr. 88, 216-223 (2008).
29. Yamagishi K, Iso H, Date C et al.: Fish, Omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nation-wide, community-based cohort of Japanese men and women. J. Am. Coll. Card. 52, 988-996 (2008).
30. Leaf A, Xiao YF, Kang JX, Billman GE: Prevention of sudden cardiac death by n-3 polyunsaturated fatty acids. Pharmacol. Ther. 98, 355-377 (2003).
31. London B, Albert C, Anderson ME et al.: Omega-3 Fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office of Dietary Supplements Omega-3 fatty acids and their role in cardiac arrhythmogenesis workshop. Circulation 116, E320-E335 (2007).
32. Schrepf R, Limmert T, Claus Weber P, Theisen K, Sellmayer A: Immediate effects of n-3 fatty acid infusion on the induction of sustained ventricular tachycardia. Lancet 363, 1441-1442 (2004).
33. Metcalf RG, Sanders P, James MJ, Cleland LG, Young GD: Effect of dietary n-3 polyunsaturated fatty acids on the inducibility of ventricular tachycardia in patients with ischemic cardiomyopathy. Am. J. Cardiol. 101, 758-761 (2008).
34. O'Keefe JH Jr, Abuissa H, Sastre A, Steinhaus DM, Harris WS: Effects of Omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am. J. Cardiol. 97, 1127-1130 (2006).
35. Christensen JH, Schmidt EB: Autonomic nervous system, heart rate variability and n-3 fatty acids. J. Cardiovasc. Med. (Hagerstown) 8(Suppl. 1), S19-S22 (2007).
36. Calò L, Bianconi L, Colivicchi F et al.: n-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J. Am. Coll. Cardiol. 45, 1723-1728 (2005).
37. von Schacky C: A review of Omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels. Vasc. Health Risk Manag. 2, 251-262 (2006).
38. Yaqoob P, Calder PC: Fatty acids and immune function: new insights into mechanisms. Br. J. Nutr. 98(Suppl. 1), S41-S45 (2007).
39. De Caterina R, Zampoll A: Omega-3 fatty acids, atherogenesis, and endothelial activation. J. Cardiovasc. Med. (Hagerstown) 8(Suppl. 1), S11-S14 (2007).
40. von Schacky C: n-3 PUFA in CVD: influence of cytokine polymorphism. Proc. Nutr. Soc. 66, 166-170 (2007).
41. Thies F, Garry JM, Yaqoob P et al.: Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 361, 477-485 (2003).
42. von Schacky C, Harris WS: Cardiovascular benefits of Omega-3 fatty acids. Cardiovasc. Res. 72, 310-315 (2007).
43. Tavazzi L, Tognoni G, Franzosi MG et al.: Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur. J. Heart Fail. 6, 635-641 (2004).
44. Burr ML, Fehily AM, Gilbert JF et al.: Effects of changes in fat, fish, and fibre intakes on death and myocardial infarction diet and reinfarction trial (DART). Lancet 2(8666), 757-761 (1989).
45. Burr ML, Ashfield-Watt PAL, Dunstan FDJ et al.: Lack of benefit of dietary advice to men with angina, results of a controlled trial. Eur. J. Clin. Nutr. 57, 193-200 (2003).
46. GISSI-HF investigators: Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 372, 1223-1230 (2008).
47. Mozaffarian D, Rimm EB: Fish intake, contaminants, and human health: evaluating the risks and the benefits. J. Am. Med. Assoc. 296, 1885-1899 (2006).
48. Leaf A, Albert CM, Josephson M et al.: For the fatty acid antiarrhythmia trial investigators. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 112, 2762-2768 (2005).
49. Raitt MH, Connor WE, Morris C et al.: Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators. A randomized controlled trial. J. Am. Med. Assoc. 293, 2884-2891 (2005).
50. Brouwer IA, Zock PL, Camm AJ et al.: SOFA Study Group. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 295, 2613-2619 (2006).
51. Jenkins DJ, Josse AR, Beyene J et al.: Fish-oil supplementation in patients with implantable cardioverter defibrillators: a meta-analysis. CMAJ 178, 157-164 (2008).
52. Wilhelm M, Tobias R, Asskali F et al.: Red blood cell Omega-3 fatty acids and the risk of ventricular arrhythmias in patients with heart failure. Am. Heart J. 155, 971-977 (2008).
53. Aarsetøy H, Pönitz V, Nilsen OB, Grundt H, Harris WS, Nilsen DW: Low levels of cellular Omega-3 increase the risk of ventricular fibrillation during the acute ischaemic phase of a myocardial infarction. Resuscitation 78, 258-264 (2008).
54. Brouwer IA, Raitt MH, Dullemeijer C et al.: Effect of fish oil on life-threatening arrhythmias in patients with implantable cardioverter defibrillators: a combined analysis of 3 trials. ISSFAL 58 (2008) (Abstract).
55. Van der Werf F, Ardissino D, Betriu A et al.: Task force on the management of acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 24, 28-66 (2003).
56. Fuster V, Rydén LE, Cannom DS: ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology Committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). Eur. Heart J. 27, 1979-2030 (2006).
57. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM: Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 105, 2595-2599 (2002).
58. Cook NR: Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin. Chem. 54, 17-23 (2008).
59. Shearer GC, Pottala JV, Harris WS: Blood cell fatty acid profiles discriminate acute coronary syndrome case better than standard cardiovascular risk factors. ISSFAL 179 (2008) (Abstract).
60. Harris WS, Lemke SL, Hansen SN et al.: Stearidonic acid-enriched soybean oil increased the Omega-3 Index, an emerging cardiovascular risk marker. Lipids 43, 805-811 (2008).